Interleukin-37: A Link Between COVID-19, Diabetes, and the Black Fungus
| dc.contributor.author | Tokajian, Sima T. | |
| dc.contributor.author | Merhi, Georgi | |
| dc.contributor.author | Al Khoury, Charbel | |
| dc.contributor.author | Nemer, Georges M. | |
| dc.contributor.department | Biochemistry and Molecular Genetics | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:38:25Z | |
| dc.date.available | 2025-01-24T11:38:25Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | The COVID-19 pandemic involved millions of people and diabetes was identified as an associated comorbidity. Initiation of systemic corticosteroids in patients suffering from severe COVID-19 was associated with lower mortality. A surge of invasive fungal infections of the maxillofacial region, namely mucormycosis, was linked to a deadly infection known as black fungus. Black fungus, diabetes, corticosteroids, and coronavirus disease 2019 (COVID-19) all have a dysregulated immune response in common, which partly could also be attributed to interleukin 37 (IL-37). IL-37, a new cytokine of the IL-1 family, known for broadly reducing innate inflammation as well as acquired immune responses. The use of corticosteroids in diabetic COVID-19 patients, crowded hospitals, and lack of medical oxygen should be carefully considered to reduce COVID-associated secondary infections. Copyright © 2022 Tokajian, Merhi, Al Khoury and Nemer. | |
| dc.identifier.doi | https://doi.org/10.3389/fmicb.2021.788741 | |
| dc.identifier.eid | 2-s2.0-85123753183 | |
| dc.identifier.uri | http://hdl.handle.net/10938/29054 | |
| dc.language.iso | en | |
| dc.publisher | Frontiers Media S.A. | |
| dc.relation.ispartof | Frontiers in Microbiology | |
| dc.source | Scopus | |
| dc.subject | Corticosteroids | |
| dc.subject | Covid-19 | |
| dc.subject | Il-37 | |
| dc.subject | Mucormycosis | |
| dc.subject | T2d | |
| dc.subject | C reactive protein | |
| dc.subject | Dexamethasone | |
| dc.subject | Gamma interferon | |
| dc.subject | Gamma interferon inducible protein 10 | |
| dc.subject | Interleukin 1 | |
| dc.subject | Interleukin 10 | |
| dc.subject | Interleukin 18 receptor | |
| dc.subject | Interleukin 1alpha | |
| dc.subject | Interleukin 1beta | |
| dc.subject | Interleukin 37 | |
| dc.subject | Interleukin 6 | |
| dc.subject | Macrophage inflammatory protein 1alpha | |
| dc.subject | Macrophage inflammatory protein 1beta | |
| dc.subject | Monocyte chemotactic protein 1 | |
| dc.subject | Oseltamivir | |
| dc.subject | Rantes | |
| dc.subject | Tumor necrosis factor | |
| dc.subject | Adaptive immunity | |
| dc.subject | Black fungus | |
| dc.subject | Body mass | |
| dc.subject | Comorbidity | |
| dc.subject | Coronavirus disease 2019 | |
| dc.subject | Cytokine storm | |
| dc.subject | Diabetes mellitus | |
| dc.subject | Enzyme linked immunosorbent assay | |
| dc.subject | Glycemic control | |
| dc.subject | Human | |
| dc.subject | Hyperglycemia | |
| dc.subject | Immune response | |
| dc.subject | Immunosuppressive treatment | |
| dc.subject | Innate immunity | |
| dc.subject | Mortality | |
| dc.subject | Mucor | |
| dc.subject | Nonhuman | |
| dc.subject | Pathogenesis | |
| dc.subject | Review | |
| dc.subject | Single nucleotide polymorphism | |
| dc.title | Interleukin-37: A Link Between COVID-19, Diabetes, and the Black Fungus | |
| dc.type | Review |
Files
Original bundle
1 - 1 of 1